Welcome to our dedicated page for Nuvation Bio SEC filings (Ticker: NUVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuvation Bio Inc. (NYSE: NUVB) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its oncology business, financial position and key agreements. On this page, you can review NUVB’s current reports on Form 8‑K and other SEC filings alongside AI-generated summaries that help explain the significance of each document.
For Nuvation Bio, Form 10‑K annual reports and Form 10‑Q quarterly reports are central sources for information on its pipeline of targeted cancer therapies, including taletrectinib (IBTROZI) for ROS1-positive non-small cell lung cancer, safusidenib for IDH1-mutant gliomas, NUV-868 and its drug-drug conjugate platform. These filings typically describe clinical programs such as the TRUST registrational studies for taletrectinib and the G203 study for safusidenib, as well as risk factors relevant to oncology drug development and commercialization.
Nuvation Bio also uses Form 8‑K to disclose material events. Recent 8‑K filings have reported preliminary financial results and net product revenue for IBTROZI, the entry into a license and collaboration agreement with Eisai Co., Ltd. for taletrectinib in multiple territories, publication of positive Phase 2 data for safusidenib, and strategic decisions such as discontinuation of NUV-1511 while continuing the underlying DDC platform. Other 8‑Ks have furnished earnings press releases and updated corporate presentations.
Investors interested in equity structure and trading can consult registration statements and periodic reports for details on Nuvation Bio’s Class A common stock and redeemable warrants, which trade on the New York Stock Exchange under the symbols NUVB and NUVB.WS. Form 4 insider transaction reports, when available, can be used to track purchases and sales of NUVB securities by directors and officers.
Stock Titan enhances access to these filings with AI-powered summaries that highlight key terms in complex agreements, explain financial disclosures in plain language and point out important milestones, such as collaboration payments or changes in clinical program status. Real-time updates from EDGAR ensure that new NUVB filings appear promptly, while structured views of 10‑K, 10‑Q, 8‑K and Form 4 documents help users quickly locate the information most relevant to their analysis of Nuvation Bio’s oncology business.
Nuvation Bio Inc. entered into a License and Collaboration Agreement with Eisai Co., Ltd. covering taletrectinib in a broad Territory including Europe, parts of the Middle East, Africa, Asia-Pacific, Canada and other countries. Eisai will pay Nuvation Bio upfront consideration of
The agreement lasts on a product-by-product basis through the applicable royalty term, after which Eisai’s license becomes non-exclusive and royalty-free for that product. Eisai and Nuvation Bio each have defined termination rights, including for material breach, certain safety issues, failure to obtain specified EU regulatory approvals by a set date, invalidation of fundamental patents in a country, or bankruptcy. Nuvation Bio also reported that it released a press release with preliminary unaudited year-end cash, cash equivalents and marketable securities and preliminary net product revenue of IBTROZI, and furnished a joint press release and an updated corporate presentation.
Nuvation Bio Inc. reported insider equity transactions by its Chief Medical Officer. On 12/01/2025, the officer exercised stock options to acquire 150,000 shares of Class A common stock at an exercise price of $2.93 per share. On the same date, the officer sold 150,000 shares of Class A common stock in an open-market transaction with a weighted-average sales price of $7.8217 per share, with individual sale prices ranging from $7.80 to $7.855.
After these transactions, the officer beneficially owned 18,000 shares of Class A common stock directly and held 165,000 stock options that remain outstanding, each option relating to Class A common stock. The option originally covered 150,000 shares, vested 25% after one year from 08/29/2022 and monthly over the following 36 months, conditioned on continued service.
A holder of Class A common stock of the issuer with symbol NUVB has filed a Form 144 indicating an intent to sell 150,000 shares through Morgan Stanley Smith Barney LLC. The planned sale has an aggregate market value of $1,173,255.00, while 342,833,433 shares of this class were outstanding.
The 150,000 shares were acquired on 12/01/2025 by exercising stock options under a registered plan, paid in cash on the same date. The filing also lists recent sales by the same seller, including 10,000 common shares on 11/26/2025 for $80,000.00 and 20,000 common shares on 11/20/2025 for $140,074.00. By signing, the seller represents they are not aware of undisclosed material adverse information about the issuer.
Nuvation Bio Inc. (NUVB) reported insider transactions by its Chief Medical Officer. On 11/25/2025, the officer exercised 10,000 stock options for Class A common stock at $3.61 per share and sold 10,000 shares at $7.50 per share, leaving 18,000 shares directly owned. On 11/26/2025, the officer again exercised 10,000 options at $3.61 and sold 10,000 shares at $8.00, with direct ownership again reported as 18,000 shares. These trades came from stock options with a $3.61 exercise price and an expiration date of 07/14/2032. After the reported option exercises, the officer still holds 470,000 stock options, which continue to vest monthly following an initial 25% vest on the one-year anniversary of 07/15/2022.
Nuvation Bio Inc. announced it is discontinuing development of NUV-1511, the first compound from its drug-drug conjugate platform, due to a lack of sufficiently consistent efficacy across patient cohorts, despite being well tolerated and showing promising signals in some patients. The company plans to use knowledge from this program to design new DDC candidates and will reallocate the
NUVB filed a notice that an affiliated holder, named in the form, plans to sell 10,000 shares of Class A common stock through Morgan Stanley Smith Barney on the NYSE, with an aggregate market value of $75,000.00. The filing states that these shares were acquired on 11/25/2025 by exercising options under a registered plan, paid in cash.
The notice also lists recent sales for the same seller over the past three months, including 20,000 common shares sold on 11/20/2025 for gross proceeds of $140,074.00, 15,000 Class A common shares sold on 11/19/2025 for $76,552.50, and 15,000 Class A common shares sold on 11/17/2025 for $71,475.00. Shares of Class A common stock outstanding were reported as 342,833,433.
Nuvation Bio Inc. (NUVB) Chief Scientific Officer reported option exercises and same-day share sales. On 11/20/2025, the insider exercised 69,051 stock options at $1.74 per share and 300,000 stock options at $1.94 per share, receiving the same number of Class A common shares.
That same day, the insider sold 69,051 and 300,000 Class A common shares at a weighted-average price of $7.227 per share in separate transactions, leaving 0 shares of common stock directly owned afterward. Following these transactions, the insider continued to hold 229,884 options with a $1.74 exercise price expiring on 01/21/2030 and 200,000 options with a $1.94 exercise price expiring on 02/27/2033.
Nuvation Bio Inc. (NUVB) reported an insider equity transaction by its Chief Medical Officer. On 11/20/2025, the officer exercised a stock option to buy 20,000 shares of Class A common stock at $1.87 per share and then sold 20,000 shares of Class A common stock in an open-market transaction at a weighted-average price of $7.0037 per share. After these transactions, the officer beneficially owned 18,000 shares of Class A common stock directly and held 450,000 stock options with an exercise price of $1.87 per share, expiring on 02/27/2034. The option vests 25% on the one-year anniversary of 02/29/2024 and monthly over the following 36 months, subject to continuous service.
Nuvation Bio Inc. (NUVB)11/19/2025, the officer exercised 200,000 stock options at an exercise price of $1.87 per share, converting them into Class A common stock. On the same date, the officer sold 200,000 Class A common shares at a weighted-average price of $7.1384 per share. After these transactions, the officer directly held 24,000 shares of Class A common stock and 300,000 stock options. The filing notes additional shares acquired through the company’s 2021 Employee Stock Purchase Plan and describes the vesting schedule for the option grant.
A shareholder of NUVB has filed a Rule 144 notice to sell up to 369,051 common shares through broker Morgan Stanley Smith Barney LLC on the NYSE. The filing lists an aggregate market value of
FAQ
What is the current stock price of Nuvation Bio (NUVB)?
What is the market cap of Nuvation Bio (NUVB)?
